| Literature DB >> 24900233 |
Bradley P Morgan1, Alexander Muci1, Pu-Ping Lu1, Xiangping Qian1, Todd Tochimoto1, Whitney W Smith1, Marc Garard1, Erica Kraynack1, Scott Collibee1, Ion Suehiro1, Adam Tomasi1, S Corey Valdez1, Wenyue Wang1, Hong Jiang1, James Hartman1, Hector M Rodriguez1, Raja Kawas1, Sheila Sylvester1, Kathleen A Elias1, Guillermo Godinez1, Kenneth Lee1, Robert Anderson1, Sandra Sueoka1, Donghong Xu1, Zhengping Wang1, Nebojsa Djordjevic1, Fady I Malik1, David J Morgans1.
Abstract
We report the design, synthesis, and optimization of the first, selective activators of cardiac myosin. Starting with a poorly soluble, nitro-aromatic hit compound (1), potent, selective, and soluble myosin activators were designed culminating in the discovery of omecamtiv mecarbil (24). Compound 24 is currently in clinical trials for the treatment of systolic heart failure.Entities:
Keywords: Omecamtiv mecarbil; cardiac myosin; small molecule enzyme activator; systolic heart failure
Year: 2010 PMID: 24900233 PMCID: PMC4007828 DOI: 10.1021/ml100138q
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345